| Citation: | Liu Zixi, Zhu Jiqiao, Ma Jun, et al. Clinical research progress of drug-reducing regimen for immunosuppressants after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 328-332. doi: 10.3969/j.issn.1674-7445.2019.03.018
|
| [1] |
郑树森, 俞军, 张武.肝移植在中国的发展现状[J].临床肝胆病杂志, 2014, 30(1):2-4. DOI: 10.3969/j.issn.1001-5256.2014.01.001.
ZHENG SS, YU J, ZHANG W. Current development of liver transplantation in China[J]. J Clin Hepatol, 2014, 30(1):2-4. DOI: 10.3969/j.issn.1001-5256.2014.01.001.
|
| [2] |
ÅBERG F, GISSLER M, KARLSEN TH, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study[J]. Hepatology, 2015, 61(2):668-677. DOI: 10.1002/hep.27538.
|
| [3] |
MENAHEM B, LUBRANO J, DUVOUX C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal Meta-analysis[J]. Liver Transpl, 2017, 23(6):836-844. DOI: 10.1002/lt.24758.
|
| [4] |
WEI Q, GAO F, ZHUANG R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5):426-437. DOI: 10.21147/j.issn.1000-9604.2017.05.07.
|
| [5] |
XING T, HUANG L, YU Z, et al. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma[J]. PLoS One, 2013, 8(8):e71251. DOI: 10.1371/journal.pone.0071251.
|
| [6] |
FIGUERAS J, PRIETO M, BERNARDOS A, et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts[J]. Transpl Int, 2006, 19(8):641-648. doi: 10.1111/tri.2006.19.issue-8
|
| [7] |
JUNG DH, HWANG S, SONG GW, et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection[J]. Liver Transpl, 2017, 23(3):330-341. DOI: 10.1002/lt.24711.
|
| [8] |
GEISSLER EK, SCHNITZBAUER AA, ZÜLKE C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1):116-125. DOI: 10.1097/TP.0000000000000965.
|
| [9] |
THORAT A, JENG LB, YANG HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4):205-211. DOI: 10.14701/ahbps.2017.21.4.205.
|
| [10] |
XU SL, ZHANG YC, WANG GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2016, 40(6):674-681. DOI: 10.1016/j.clinre.2016.03.006.
|
| [11] |
LEE KW, SEO YD, OH SC, et al. What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma?[J]. Hepatol Res, 2016, 46(6):593-600. DOI: 10.1111/hepr.12588.
|
| [12] |
DUN B, XU H, SHARMA A, et al. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid[J]. Int J Clin Exp Pathol, 2013, 6(12):2880-2886. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24294374
|
| [13] |
LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1):3-26. DOI: 10.1002/lt.23566.
|
| [14] |
中国医师协会器官移植医师分会, 中华医学会外科学分会器官移植学组, 中华医学会器官移植学分会肝移植学组.中国肝移植受者代谢病管理专家共识(2015版)[J].中华消化外科杂志, 2015, 14(8):601-605. DOI: 10.3760/cma.j.issn.1673-9752.2015.08.001.
Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Division of Transplantation of Branch of Surgery of Chinese Medical Association, Liver Transplantation Group of Organ Transplantation Branch of Chinese Medical Association. Expert consensus on management of metabolic diseases in Chinese liver transplant recipients (2015 edition) [J]. Chin J Dig Surg, 2015, 14(8):601-605. DOI: 10.3760/cma.j.issn.1673-9752.2015.08.001.
|
| [15] |
CHI MJ, LIANG CK, LEE WJ, et al. Association of new-onset diabetes mellitus in older people and mortality in Taiwan: a 10-year nationwide population-based study[J]. J Nutr Health Aging, 2017, 21(2):227-232. DOI: 10.1007/s12603-016-0751-9.
|
| [16] |
SGOURAKIS G, RADTKE A, FOUZAS I, et al. Corticosteroid-free immunosuppression in liver transplantation: a Meta-analysis and Meta-regression of outcomes[J]. Transpl Int, 2009, 22(9):892-905. DOI: 10.1111/j.1432-2277.2009.00893.x.
|
| [17] |
OTHMAN N, GHEITH O, AL-OTAIBI T, et al. Assessment of diabetes knowledge among renal transplant recipients with posttransplant diabetes mellitus: Kuwait experience[J]. Exp Clin Transplant, 2019, 17(Suppl 1):277-285. DOI: 10.6002/ect.MESOT2018.P126.
|
| [18] |
LING Q, XIE H, LU D, et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population[J]. J Hepatol, 2013, 58(2):271-277. DOI: 10.1016/j.jhep.2012.09.025.
|
| [19] |
CRUZ CM, PEREIRA S, GANDARA J, et al. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation patients with nephrotoxicity[J]. Transplant Proc, 2016, 48(7):2341-2343. DOI: 10.1016/j.transproceed.2016.06.033.
|
| [20] |
KIM WR, LAKE JR, SMITH JM, et al. OPTN/SRTR 2016 annual data report: liver[J]. Am J Transplant, 2018, 18 (Suppl 1):172-253. DOI: 10.1111/ajt.14559.
|
| [21] |
ROSSI AP, VELLA JP. Acute kidney disease after liver and heart transplantation[J]. Transplantation, 2016, 100(3):506-514. DOI: 10.1097/TP.0000000000000916.
|
| [22] |
ABDEL-KHALEK EE, ALREFAEY AK, YASSEN AM, et al. Renal dysfunction after living-donor liver transplantation: experience with 500 cases[J]. J Transplant, 2018:5910372. DOI: 10.1155/2018/5910372.
|
| [23] |
SPARROW HG, SWAN JT, MOORE LW, et al. Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1[J]. Kidney Int, 2019, 95(4):905-913. DOI: 10.1016/j.kint.2018.11.030.
|
| [24] |
YE L, MAO W. Metabonomic biomarkers for risk factors of chronic kidney disease[J]. Int Urol Nephrol, 2016, 48(4):547-552. DOI: 10.1007/s11255-016-1239-6.
|
| [25] |
CHARLTON MR, WALL WJ, OJO AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation[J]. Liver Transpl, 2009, 15(11):S1-S34. DOI: 10.1002/lt.21877.
|
| [26] |
谢琴芬, 郑树森.肝癌患者肝移植后的免疫抑制剂应用[J].中华器官移植杂志, 2013, 34(9):573-575.DOI: 10.3760/cma.j.issn.0254-1785.2013.09.018.
XIE QF, ZHENG SS. Application of immunosuppressive agents after liver transplantation in patients with hepatocellular carcinoma [J]. Chin J Organ Transplant, 2013, 34(9):573-575. DOI: 10.3760/cma.j.issn.0254-1785.2013.09.018.
|
| [27] |
FISCHER L, SALIBA F, KAISER GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study[J].Transplantation, 2015, 99(7):1455-1462. DOI: 10.1097/TP.0000000000000555.
|
| [28] |
ZIDAN AS. Taste-masked tacrolimus-phospholipid nanodispersions: dissolution enhancement, taste masking and reduced gastric complications[J]. Pharm Dev Technol, 2017, 22(2):173-183. DOI: 10.3109/10837450.2016.1138131.
|
| [29] |
HOLT CD. Overview of immunosuppressive therapy in solid organ transplantation[J]. Anesthesiol Clin, 2017, 35(3):365-380. DOI: 10.1016/j.anclin.2017.04.001.
|
| [30] |
THANAVARO J, TAYLOR J, VITT L, et al. Predictors and outcomes of acute kidney injury after cardiac surgery[J]. Nephrol Nurs J, 2019, 46(1):31-40.
|
| [31] |
BAEK SD, JANG M, KIM W, et al. Benefits of intraoperative continuous renal replacement therapy during liver transplantation in patients with renal dysfunction[J]. Transplant Proc, 2017, 49(6):1344-1350. DOI: 10.1016/j.transproceed.2017.03.094.
|
| [32] |
ZHAO HL, LU Y, LING W. Change in albuminuria as a surrogate endpoint in chronic kidney disease[J]. Lancet Diabetes Endocrinol, 2019, 7(5):335-336. DOI: 10.1016/S2213-8587(19)30085-3.
|
| [33] |
HEERSPINK HJL, CORESH J, GANSEVOORT RT, et al. Change in albuminuria as a surrogate endpoint in chronic kidney disease - authors' reply[J]. Lancet Diabetes Endocrinol, 2019, 7(5):336-337. DOI: 10.1016/S2213-8587(19)30080-4.
|
| [34] |
FENG S, BUCUVALAS J. Tolerance after liver transplantation: where are we? [J]. Liver Transpl, 2017, 23(12):1601-1614. DOI: 10.1002/lt.24845.
|
| [35] |
LEVITSKY J, FENG S. Tolerance in clinical liver transplantation[J]. Hum Immunol, 2018, 79(5):283-287. DOI: 10.1016/j.humimm.2017.10.007.
|
| [36] |
WONG TC, LO CM, FUNG JY. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation[J]. Expert Opin Emerg Drugs, 2017, 22(2):123-136. DOI: 10.1080/14728214.2017.1330884.
|
| [37] |
DHANASEKARAN R. Management of immunosuppression in liver transplantation[J]. Clin Liver Dis, 2017, 21(2):337-353. DOI: 10.1016/j.cld.2016.12.007.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: